Treatment of Acute Myelocytic Leukemia: A Study by Cancer and Leukemia Group B

In a randomized study of acute myelocytic leukemia (AML), 352 patients of all ages were treated for remission induction by one of the four regimens: 7 days of cytosine arabinoside (ara-C) by continuous intravenous (i.v.) infusion or bolus injection every 12 hr, together with daunorubicin (DNR) by ra...

Full description

Saved in:

Bibliographic Details
Published in:	Blood Vol. 58; no. 6; pp. 1203 - 1212
Main Authors:	Rai, Kanti R., Holland, James F., Glidewell, Oliver J., Weinberg, Vivian, Brunner, Kurt, Obrecht, J.P., Preisler, Harvey D., Nawabi, Ismat W., Prager, David, Carey, Robert W., Cooper, M. Robert, Haurani, Farid, Hutchison, J.L., Silver, Richard T., Falkson, Geoffrey, Wiernik, Peter, Hoagland, H. Clark, Bloomfield, Clara D., James, G. Watson, Gottlieb, Arlan, Ramanan, S.V., Blom, Johannes, Nissen, Nis I., Bank, Arthur, Ellison, Rose Ruth, Kung, Faith, Henry, Patrick, McIntyre, O. Ross, Kaan, Sze K.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-12-1981
Subjects:	Acute Disease Adolescent Adult Cytarabine - therapeutic use Daunorubicin - therapeutic use Female Humans Leukemia, Erythroblastic, Acute - diagnosis Leukemia, Erythroblastic, Acute - drug therapy Leukemia, Erythroblastic, Acute - mortality Leukemia, Myeloid, Acute - diagnosis Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - mortality Male Middle Aged Random Allocation Time Factors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!